$20.10
1.98%
NYSE, Nov 19, 03:58 pm EST. Closed.

Fortrea Stock price

$20.15
-2.27 10.12% 1M
+6.44 46.97% 6M
+2.90 16.81% YTD
+10.11 100.70% 1Y
-12.17 37.65% 3Y
-9.95 33.06% 5Y
-9.95 33.06% 10Y
-9.95 33.06% 20Y
NYSE, Closing price Thu, Nov 19 2026
-0.35 1.71%

Is Fortrea a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$2.8b
Net debt
$834.7m
Cash
$220.6m
Shares outstanding
96.5m
Valuation
P/E
negative
P/S | estimate
0.7 | 0.7
EV/Sales | estimate
1.1 | 1.0
EV/FCF | ex SBC
16.6 | 23.8
P/B
3.7
Financial Health
Equity Ratio
20.8%
Return on Equity
-175.0%
ROCE
2.6%
ROIC
3.1%
Debt/Equity
2.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$50.8m | 1.9%
SBC as % of FCF
30.1%
SBC Growth 1Y
-32.2%
Share Count Growth 1Y
4.7%
Shareholder Yield
-4.7%
Financials
Revenue | estimate
$2.7b | $2.7b
EBITDA
$124.0m
EBIT
$45.3m
Net Income
$-68.7m
Free Cash Flow | ex SBC
$169.0m | $118.2m
Growth
Revenue | estimate
-3.4% | 0.3%
EBITDA
924.8%
EBIT
167.2%
Net Income
93.2%
Free Cash Flow
1,400.0%
Margin
Gross
20.0%
EBITDA
4.7%
EBIT
1.7%
Net
-2.6%
Free Cash Flow | ex SBC
6.3% | 4.4%
More
EPS
$-0.7
FCF per Share
$1.8
Short interest
10.4%
Employees
14k
Rev per Employee
$190.0k

Fortrea Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fortrea forecast:

12x Buy
67%
5x Hold
28%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Fortrea forecast:

Buy
67%
Hold
28%
Sell
6%

Fortrea Events

Past Events
OCT
29
Q3 2026 Earnings Call
22 days ago
JUL
29
Q2 2026 Earnings Call
4 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
FEB
26
Q4 2025 Earnings Call
9 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
2
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Fortrea

Sep '26
+/-
%
2,667 2,667
3% 3%
100%
- Direct Costs 2,133 2,133
5% 5%
80%
533 533
4% 4%
20%
- Selling and Administrative Expenses 409 409
18% 18%
15%
- Research and Development Expense - -
-
-
124 124
925% 925%
5%
- Depreciation and Amortization 79 79
1% 1%
3%
EBIT (Operating Income) EBIT 45 45
167% 167%
2%
Net Profit -69 -69
93% 93%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Fortrea directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortrea Stock News

Neutral
GlobeNewsWire
●
22 days ago
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation
Neutral
GlobeNewsWire
●
28 days ago
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
More Fortrea News

Company Profile

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.

Head office United States
CEO Mr. Thakrala
Employees 14,000
Founded 2023
Website www.fortrea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today